Page last updated: 2024-10-25

deferoxamine and Headache

deferoxamine has been researched along with Headache in 1 studies

Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.

Headache: The symptom of PAIN in the cranial region. It may be an isolated benign occurrence or manifestation of a wide variety of HEADACHE DISORDERS.

Research Excerpts

ExcerptRelevanceReference
"Deferasirox is a once-daily, oral iron chelator developed for treating transfusional iron overload."9.12A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. ( Alberti, D; Bernaudin, F; Coates, T; Eckman, J; Files, B; Fischer, R; Forni, GL; Fung, E; Hassell, K; Holland, J; Kelly, P; Lane, P; Marks, P; Mueller, BU; Okpala, I; Onyekwere, O; Porter, J; Ressayre-Djaffer, C; Swerdlow, P; Vichinsky, E; Wilson, F, 2007)
"Deferasirox is a once-daily, oral iron chelator developed for treating transfusional iron overload."5.12A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. ( Alberti, D; Bernaudin, F; Coates, T; Eckman, J; Files, B; Fischer, R; Forni, GL; Fung, E; Hassell, K; Holland, J; Kelly, P; Lane, P; Marks, P; Mueller, BU; Okpala, I; Onyekwere, O; Porter, J; Ressayre-Djaffer, C; Swerdlow, P; Vichinsky, E; Wilson, F, 2007)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Vichinsky, E1
Onyekwere, O1
Porter, J1
Swerdlow, P1
Eckman, J1
Lane, P1
Files, B1
Hassell, K1
Kelly, P1
Wilson, F1
Bernaudin, F1
Forni, GL1
Okpala, I1
Ressayre-Djaffer, C1
Alberti, D1
Holland, J1
Marks, P1
Fung, E1
Fischer, R1
Mueller, BU1
Coates, T1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomized, Open Label, Phase II Study on Safety and Efficacy of Long Term Treatment of ICL670 Relative to Deferoxamine in Sickle Cell Disease Patients With Transfusional Hemosiderosis[NCT00067080]Phase 2195 participants (Actual)Interventional2003-05-31Completed
Clinical Importance of Treating Iron Overload in Sickle Cell Disease[NCT00981370]Phase 31 participants (Actual)Interventional2009-04-30Terminated (stopped due to 1 consented patient never started on study drug, lost to follow up)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trials

1 trial available for deferoxamine and Headache

ArticleYear
A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease.
    British journal of haematology, 2007, Volume: 136, Issue:3

    Topics: Administration, Oral; Adolescent; Adult; Alanine Transaminase; Anemia, Sickle Cell; Benzoates; Blood

2007
A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease.
    British journal of haematology, 2007, Volume: 136, Issue:3

    Topics: Administration, Oral; Adolescent; Adult; Alanine Transaminase; Anemia, Sickle Cell; Benzoates; Blood

2007
A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease.
    British journal of haematology, 2007, Volume: 136, Issue:3

    Topics: Administration, Oral; Adolescent; Adult; Alanine Transaminase; Anemia, Sickle Cell; Benzoates; Blood

2007
A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease.
    British journal of haematology, 2007, Volume: 136, Issue:3

    Topics: Administration, Oral; Adolescent; Adult; Alanine Transaminase; Anemia, Sickle Cell; Benzoates; Blood

2007